Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

{"title":"Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia","authors":"","doi":"10.1016/j.bneo.2024.100038","DOIUrl":null,"url":null,"abstract":"<div><h3>Abstract</h3><div>The combination of a hypomethylating agent (HMA) and venetoclax (VEN) is approved for adults aged &gt;75 years with newly diagnosed acute myeloid leukemia (AML) as well as those ineligible for intensive chemotherapy (IC). HMA/VEN is increasingly substituted for IC in adults with AML aged &lt;75 years, particularly in those with adverse cytogenetic and molecular features. When patients fail to respond or relapse after HMA/VEN, the utility of salvage IC is largely unknown. We performed a retrospective single-institution study and identified 46 patients who received IC after HMA/VEN, including 24 patients who received HMA/VEN as their first treatment for AML. This population had complete remission (CR)/CR with incomplete count recovery (CRi)/morphologic leukemia-free state rate of 37%, CR/CRi rate of 28%, and a median overall survival (mOS) of 7.2 months (95% confidence interval, 5.0-10.3). Patients who relapsed after an initial response to HMA/VEN and subsequently received IC were more likely to achieve a CR/CRi than those refractory to HMA/VEN (50% vs 19%; <em>P</em> = .04), although there was no statistically significant difference in survival (mOS, 8.8 vs 5.4 months; <em>P</em> = .64). Age &gt;65 years predicted poorer survival (mOS, 4.3 vs 10.6 months; <em>P</em> &lt; .001). IC after HMA/VEN should be further studied and chosen with caution.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Neoplasia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950328024000384","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The combination of a hypomethylating agent (HMA) and venetoclax (VEN) is approved for adults aged >75 years with newly diagnosed acute myeloid leukemia (AML) as well as those ineligible for intensive chemotherapy (IC). HMA/VEN is increasingly substituted for IC in adults with AML aged <75 years, particularly in those with adverse cytogenetic and molecular features. When patients fail to respond or relapse after HMA/VEN, the utility of salvage IC is largely unknown. We performed a retrospective single-institution study and identified 46 patients who received IC after HMA/VEN, including 24 patients who received HMA/VEN as their first treatment for AML. This population had complete remission (CR)/CR with incomplete count recovery (CRi)/morphologic leukemia-free state rate of 37%, CR/CRi rate of 28%, and a median overall survival (mOS) of 7.2 months (95% confidence interval, 5.0-10.3). Patients who relapsed after an initial response to HMA/VEN and subsequently received IC were more likely to achieve a CR/CRi than those refractory to HMA/VEN (50% vs 19%; P = .04), although there was no statistically significant difference in survival (mOS, 8.8 vs 5.4 months; P = .64). Age >65 years predicted poorer survival (mOS, 4.3 vs 10.6 months; P < .001). IC after HMA/VEN should be further studied and chosen with caution.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人急性髓性白血病患者使用低甲基化药物和 Venetoclax 后的强化化疗
摘要低甲基化药物(HMA)和 Venetoclax(VEN)的联合用药已被批准用于年龄为 75 岁的新诊断急性髓性白血病(AML)成人患者以及不符合强化化疗(IC)条件的患者。在 75 岁的成人急性髓细胞白血病患者中,HMA/VEN 越来越多地取代 IC,尤其是那些细胞遗传学和分子特征不良的患者。当患者接受HMA/VEN治疗后无反应或复发时,挽救性IC的效用在很大程度上还不得而知。我们进行了一项单机构回顾性研究,确定了 46 名在 HMA/VEN 后接受 IC 治疗的患者,其中包括 24 名首次接受 HMA/VEN 治疗的急性髓细胞性白血病患者。这些患者的完全缓解(CR)/CR伴不完全计数恢复(CRi)/无形态白血病状态率为37%,CR/CRi率为28%,中位总生存期(mOS)为7.2个月(95%置信区间,5.0-10.3)。与HMA/VEN难治性患者相比,HMA/VEN初始反应后复发并随后接受IC治疗的患者更有可能获得CR/CRi(50% vs 19%;P = .04),但生存期(mOS,8.8个月 vs 5.4个月;P = .64)没有显著统计学差异。65岁的患者生存率较低(mOS,4.3 个月 vs 10.6 个月;P = .001)。应进一步研究 HMA/VEN 后的 IC,并谨慎选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1